2'-Fucosyllactose Composition for RNA Virus Prevention via Gut Microbiota Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective prevention and reduction of symptoms of viral infections, particularly for RNA viruses like Respiratory Syncytial virus (RSV), without relying on antiviral treatments, and in a manner that is compatible with a normal diet and does not compromise taste or health, while maintaining overall health and ease of implementation.
Innovation Solution
A composition comprising 2'-fucosyllactose (2'-FL) is administered orally to increase the production of short-chain fatty acids (SCFA), particularly acetate, in the distal colon, thereby enhancing protection against RNA-virus infections, preferably Group IV type viruses, by increasing acetate levels in circulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral treatments are used to prevent and reduce symptoms of viral infections, then the effectiveness of treatment is improved, but the complexity of treatment and potential adverse effects increase
Solution Approach 1:
The patent uses 2'-FL as an intermediary substance that indirectly prevents viral infections by modulating the gut microbiota and increasing SCFA production, rather than directly attacking the virus. This intermediary approach reduces treatment complexity while maintaining effectiveness, as 2'-FL naturally promotes beneficial bacterial growth which in turn produces antiviral compounds.
Solution Approach 2:
The invention enables the body's own immune system to fight viral infections by enhancing the production of short-chain fatty acids through 2'-FL supplementation. The gut microbiota performs the antiviral function autonomously by converting 2'-FL into SCFAs, eliminating the need for complex external antiviral interventions.
2Reliability
If complex antiviral treatments are administered, then the protection against viral infections is improved, but the compatibility with normal diet and ease of implementation deteriorates
Solution Approach 1:
The patent changes the approach from direct antiviral intervention to modifying dietary parameters by introducing 2'-FL. This simple dietary parameter change naturally leads to increased SCFA production and enhanced viral protection, making the solution easily implementable within normal dietary patterns without complex administration protocols.
3Reliability
If 2'-FL is administered to increase SCFA production, then the protection against RNA-virus infections is improved, but the quantity of substance required increases
Solution Approach 1:
The patent employs preliminary action by administering 2'-FL in advance to establish a reservoir of beneficial gut bacteria and their SCFA-producing capacity before viral exposure occurs. This preparatory supplementation ensures that when RNA viruses are encountered, the body already has enhanced antiviral defenses through pre-established high SCFA production, reducing the need for large quantities during acute infection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The increase in acetate production in the gut leads to reduced viral load in the respiratory tract, shorter contagious periods, and fewer symptoms, providing effective prevention and treatment of RNA-virus infections without adverse effects on taste or health.
Implementation Method 1
A composition comprising 2'-fucosyllactose (2'-FL) is administered orally to increase the production of short-chain fatty acids (SCFA), particularly acetate, in the distal colon
Data Source
AI summary
A composition comprising 2'-fucosyllactose (2'-FL) for use in the prevention against and / or the treatment of RNA-virus infection; preferably the composition is a nutritional composition.